Contact
searchSearch
HMP Global

Advertisement

ADVERTISEMENT

Medication Treatments

News
Using Phone App Doesn’t Improve MAT Adherence in Small Study
09/08/2021
In a small trial led by researchers from the University of Washington and conducted in Seattle and Boston, use of a video smartphone app to confirm adherence to buprenorphine for treating opioid use disorder did not reduce illicit drug use or...
In a small trial led by researchers from the University of Washington and conducted in Seattle and Boston, use of a video smartphone app to confirm adherence to buprenorphine for treating opioid use disorder did not reduce illicit drug use or...
In a small trial led by...
09/08/2021
Addiction Professional
News
Experimental Opioid Vaccine Being Studied at Columbia
08/31/2021
Researchers at Columbia University’s Vagelos College of Physicians and Surgeons are now conducting a Phase 1a/1b clinical trial for the first vaccine to be tested in the U.S. for opioid use disorder.
Researchers at Columbia University’s Vagelos College of Physicians and Surgeons are now conducting a Phase 1a/1b clinical trial for the first vaccine to be tested in the U.S. for opioid use disorder.
Researchers at Columbia...
08/31/2021
Addiction Professional
News
NIDA Awards $2.5 Million for Study of App to Augment MAT
08/24/2021
NIDA has awarded a 5-year, $2.5 million grant to research scientists at the University of Arkansas for Medical Sciences to study whether a cell phone app can reduce relapses rates in individuals with opioid use disorder.
NIDA has awarded a 5-year, $2.5 million grant to research scientists at the University of Arkansas for Medical Sciences to study whether a cell phone app can reduce relapses rates in individuals with opioid use disorder.
NIDA has awarded a 5-year, $2.5...
08/24/2021
Addiction Professional
News
As Overdose Rates Climb, Community Groups Face Naloxone Shortage
08/18/2021
With overdoses soaring across the United States, groups that distribute the opioid overdose-reversal medication naloxone say they are struggling to maintain an adequate supply, and Pfizer said it could take until February for it to catch up...
With overdoses soaring across the United States, groups that distribute the opioid overdose-reversal medication naloxone say they are struggling to maintain an adequate supply, and Pfizer said it could take until February for it to catch up...
With overdoses soaring across...
08/18/2021
Addiction Professional
News
NCAD West | MAT Options Show Promise in Treatment of SUD
08/14/2021
On Saturday at NCAD West, Valerie Carrejo, MD, FAAFP, FASAM, associate professor and addiction medicine fellowship program director for the University of New Mexico Department of Family and Community Medicine, discussed 3 FDA-approved...
On Saturday at NCAD West, Valerie Carrejo, MD, FAAFP, FASAM, associate professor and addiction medicine fellowship program director for the University of New Mexico Department of Family and Community Medicine, discussed 3 FDA-approved...
On Saturday at NCAD West,...
08/14/2021
Addiction Professional
Fast track designation
Lyndra Therapeutics’ Weekly OUD Treatment Gets Fast Track Designation from FDA
07/30/2021
Lyndra Therapeutics, a Watertown, Massachusetts-based clinical-stage biotech firm, announced that its oral, extended-release medication for treatment of opioid use disorder has received a Fast Track designation by the FDA.
Lyndra Therapeutics, a Watertown, Massachusetts-based clinical-stage biotech firm, announced that its oral, extended-release medication for treatment of opioid use disorder has received a Fast Track designation by the FDA.
Lyndra Therapeutics, a...
07/30/2021
Addiction Professional
News
Study: Higher Doses of Buprenorphine Safe, Well Tolerated in Emergency Departments
07/20/2021
When administered by emergency department caregivers, high-dose buprenorphine therapy is safe and well tolerated in individuals with opioid use disorder who are experiencing withdrawal symptoms, according to results of a study supported by...
When administered by emergency department caregivers, high-dose buprenorphine therapy is safe and well tolerated in individuals with opioid use disorder who are experiencing withdrawal symptoms, according to results of a study supported by...
When administered by emergency...
07/20/2021
Addiction Professional
News
Once-Weekly Oral Buprenorphine Formulation Shows Potential in Study
07/01/2021
Lyndra Therapeutics announced that in a recent preclinical study, its oral extended-release buprenorphine capsule showed sustained suppression of opioid self-administration in an animal model, potentially paving the way for a new weekly oral...
Lyndra Therapeutics announced that in a recent preclinical study, its oral extended-release buprenorphine capsule showed sustained suppression of opioid self-administration in an animal model, potentially paving the way for a new weekly oral...
Lyndra Therapeutics announced...
07/01/2021
Addiction Professional
News
DEA Finalizes Measures to Ease Process for Providers to Add Mobile Components
06/29/2021
To expand access to medication-assisted treatment for opioid use disorder, particularly in rural areas with limited treatment options, DEA on Monday announced that it has published a final rule that allows registrants who are authorized to...
To expand access to medication-assisted treatment for opioid use disorder, particularly in rural areas with limited treatment options, DEA on Monday announced that it has published a final rule that allows registrants who are authorized to...
To expand access to...
06/29/2021
Behavioral Healthcare Executive
News
Small Number of Clinicians Account for Half of All Buprenorphine Prescriptions
06/04/2021
Half of all prescriptions for buprenorphine to treat opioid use disorder in 2017 and 2018 were written by just 4.9% of the physicians and other providers who were waivered to provide the drug, according to research published by RAND Corp.
Half of all prescriptions for buprenorphine to treat opioid use disorder in 2017 and 2018 were written by just 4.9% of the physicians and other providers who were waivered to provide the drug, according to research published by RAND Corp.
Half of all prescriptions for...
06/04/2021
Addiction Professional

Advertisement

Advertisement

Browse Our Other Brands

Psych NP Institute

 

Psych Congress Network

 

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement